NVS-ZP7-4 is an inhibitor of the zinc transporter SLC39A7 (ZIP7). It induces apoptosis in TALL-1 human T cell acute lymphoblastic leukemia cells, an effect that can be reduced by expression of the ZIP7 point mutant ZIP7V430E. NVS-ZP7-4 (20 µM) increases endoplasmic reticulum, but not cytosolic, zinc levels in U2OS cells. It inhibits ferroptosis induced by erastin (Item No. 17754) in MDA-MB-231 and RCC4 cells when used at a concentration of 10 µM.
NVS-ZP7-4 is an inhibitor of the zinc transporter SLC39A7 (ZIP7). It induces apoptosis in TALL-1 human T cell acute lymphoblastic leukemia cells, an effect that can be reduced by expression of the ZIP7 point mutant ZIP7V430E. NVS-ZP7-4 (20 µM) increases endoplasmic reticulum, but not cytosolic, zinc levels in U2OS cells. It inhibits ferroptosis induced by erastin (Item No. 17754) in MDA-MB-231 and RCC4 cells when used at a concentration of 10 µM.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.